IFF Q3 2026 Earnings: Sales Rise While GAAP EPS Turns Negative

IFF (NYSE: IFF) reported Q3 2026 net sales of $1.942 billion, up 4% from $1.869 billion a year earlier, while diluted EPS from continuing operations fell to a loss of $0.50 from earnings of $0.39. Adjusted operating EBITDA was $403 million with a 20.8% margin, supported by growth across all three divisions. Except for cash flow and certain leverage metrics, the results reflect continuing operations, with Food Ingredients and the SCL businesses classified as discontinued operations.

Core Financial Results

Sales growth translated into a smaller 3% increase in gross profit, reducing gross margin by approximately 30 basis points. Operating profit declined 16% as selling and administrative expenses rose 11%, research and development spending increased 5%, and IFF recorded a $23 million goodwill impairment.

Below operating profit, a $236 million loss on assets classified as held for sale contributed to a swing from pretax income of $130 million to a pretax loss of $134 million. Adjusted results were more favorable, with reported adjusted operating EBITDA up 5% and comparable currency-neutral EBITDA up 6% on volume growth.

Adjusted operating EBITDA and adjusted EPS excluding amortization are non-GAAP measures. Comparable results exclude divestitures, while currency-neutral results remove the effects of foreign-currency translation.

Business and Segment Performance

Scent produced the fastest profit growth, while Taste benefited from broad regional demand. Health & Biosciences remained the slowest-growing division, although it still recorded modest gains in sales and adjusted EBITDA.

Taste grew across every region, led by a double-digit increase in Greater Asia. Volume growth drove the division’s 7% comparable currency-neutral EBITDA increase.

Health & Biosciences benefited from mid-single-digit growth in Food Biosciences and Grain Processing, which more than offset a decline in Health. Its EBITDA improvement was split evenly between volume growth and favorable net pricing relative to input costs.

Scent was led by high-single-digit growth in Consumer Fragrances. Fine Fragrance and Fragrance Ingredients both grew at mid-single-digit rates, helping adjusted EBITDA rise faster than sales.

Cash Flow, Leverage, and Capital Allocation

Cash flow figures cover the first nine months of 2026 and include both continuing and discontinued operations. Operating cash flow rose by $288 million to $820 million, while free cash flow increased by $245 million to $371 million. Capital expenditures were $449 million, compared with $406 million in the prior-year period.

Working-capital movements included a $204 million contribution from accounts payable, compared with $28 million a year earlier. Inventory used $54 million of cash versus $129 million previously, although receivables used $291 million, up from $195 million.

At September 30, balance-sheet cash and cash equivalents were $272 million, down from $347 million at the end of 2025. Short-term borrowings increased to $1.538 billion from $1.254 billion, while long-term debt was nearly unchanged at $4.735 billion. Net debt to credit-adjusted EBITDA was 2.75 times and included continuing and discontinued operations.

IFF completed its $500 million accelerated share repurchase program. Total treasury-stock purchases were $584 million for the first nine months, while cash dividends totaled $306 million.

Adjusted Growth and GAAP Earnings Moved in Opposite Directions

The quarter’s central issue was the divergence between underlying operating growth and reported earnings. Volume growth lifted comparable currency-neutral adjusted EBITDA by 6%, but GAAP operating profit declined as selling and administrative expenses increased by $39 million and IFF recorded a goodwill impairment.

The larger difference appeared below operating profit. The $236 million held-for-sale loss exceeded the quarter’s $160 million operating profit, contributing to the pretax and continuing-operations losses. Because adjusted operating EBITDA excludes held-for-sale losses and other specified items, it showed improving operating performance while GAAP EPS turned negative.

Full-Year Guidance

IFF raised the lower ends of all four principal full-year guidance ranges while leaving the upper ends unchanged. The revisions reflect performance through the first nine months, but management expects fourth-quarter profitability to soften, particularly in Health & Biosciences, because of higher costs and reinvestment in the business.

Based on recent exchange rates, IFF continues to expect foreign currency to add approximately 1 percentage point to 2026 sales growth and approximately 2 percentage points to adjusted operating EBITDA growth. The company also said the Food Ingredients separation remains on track to close by the end of Q2 2027.

Recent Insider Transactions

Four of the recent insider records supplied included a clear transaction direction, price, ownership type, and value. These transactions are presented without inferring insiders’ views about the company’s valuation or outlook.

Six additional records from May 2026 did not provide a transaction direction or value and are therefore excluded from the table.

Risks Investors Should Watch

• Fourth-quarter margin pressure: Management expects softer profitability, especially in Health & Biosciences, because of higher costs and reinvestment.
• Uneven segment growth: Health & Biosciences generated only 1% comparable currency-neutral sales growth, and growth in other businesses had to offset a decline in Health.
• Portfolio-separation effects: The pending Food Ingredients transaction has already contributed to significant held-for-sale accounting charges. Additional divestiture costs or gains and losses could continue to create volatility in GAAP results.
• Leverage and liquidity: Net debt to credit-adjusted EBITDA was 2.75 times, short-term borrowings increased, and balance-sheet cash declined despite stronger nine-month operating cash flow.

Summary

IFF’s Q3 2026 sales and adjusted EBITDA increased as volume growth supported all three divisions, with Scent delivering the fastest profit growth. GAAP earnings moved in the opposite direction because of higher operating expenses and a $236 million held-for-sale loss. The higher lower bounds of full-year guidance indicate greater confidence in the 2026 range, but fourth-quarter cost pressure, slower Health & Biosciences growth, leverage, and execution of the Food Ingredients separation remain the main areas to monitor.